ODTC Company Profile and Key Details

Odonate Therapeutics, Inc. earnings surprise history is a mixed track record. The quarter that ended July 27, 2021, missed forecasts by 75.76%. The prior quarter beat by 11.11%. Over the last six quarters, Apple has recorded several small beats. These include -2.94% in April 28, 2020.

Odonate Therapeutics, Inc. has 356.00 shares outstanding. The public float is 35.14 million shares, elevated short interest at 2.31% of float. This equals 4.00 shares. The short ratio is 0.59 days.

Odonate Therapeutics, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $12.98. This means the shares are trading above this model’s fair value.

Our AI price prediction model suggests that Odonate Therapeutics, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term.

The stock is currently trading near its 52-week low $22.00 thousand and $358.00 thousand. With a market capitalization of about $8.05 billion, Odonate Therapeutics, Inc. is classified as a mid-cap and shows lower-than-market volatility (beta ~0.42). Headquartered in New York City, NY, Odonate Therapeutics, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Kevin C. Tang, the company employs approximately 137 people and listed since December 07, 2017. Odonate Therapeutics, Inc., a pharmaceutical company established in 2013 and headquartered in New York, New York, is dedicated to creating treatments for cancer.

Valuation shows Odonate Therapeutics, Inc. trading at a premium to the broader market with a P/E of 3227.62.

Odonate Therapeutics, Inc. trades at a P/E ratio of 3227.62, slightly above the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 218.64 reflecting a rich premium to book value. The P/FCF stands at 920.61, also above market averages. Compared to sector medians, Odonate Therapeutics, Inc. P/S is trading at a discount to the sector, and the P/B is far higher than peers, underscoring the brand and earnings power premium investors assign to the stock.